SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has rallied to a fresh 52-week high as traders position ahead of the Q3 report, focusing on BRIUMVIs sales growth and possible guidance changes. The move has also fueled unconfirmed Sanofi buyout and short-squeeze speculation, while some traders caution that the rally may have priced in strong results.

Lennar Corp. engages in the provision of real estate related financial and investment management services. It operates through the following segments: Homebuilding, Financial Services, Multifamily, and Lennar Other. The Homebuilding segment refers to the construction and sale of single-family attached and detached homes and the purchase, development, and sale of residential land directly and through entities. The Financial Services segment focuses on mortgage financing, title, and closing services for buyers. The Multifamily segment is involved in the development, construction, and property management of multifamily rental properties. The Lennar Other segment includes funds, asset management platform, and strategic investments in technology companies. The company was founded in 1954 and is headquartered in Miami, FL.

Lennar Corp. - Ordinary Shares - Class A

Lennar Corp.

Berkshires disclosed accumulation of a large Lennar stake has fueled bargain-buying interest, but traders are debating it against Hunterbrooks short-report allegations about Lennars transactions with spinoff Millrose. The dispute adds to concerns over weak results and outlook, pressured affordability, and elevated mortgage rates.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

A Northland upgrade citing C3 Code as a potential growth driver for agentic AI has renewed interest in C3.ai, alongside unusual call-option activity and short-squeeze speculation. Traders are divided between optimism about the product and enterprise AI demand, and concern over declining revenue and continued losses.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. The firm offers annealing and gate-model quantum computing technologies. It provides professional services that assist customers in identifying and implementing quantum computing applications and selling quantum computer systems to customers. The company was founded by Eric Ladizinsky in 1999 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave shares are drawing attention amid a steep selloff across quantum-computing stocks, with traders questioning whether high valuations, limited near-term commercialization and competition from classical AI can support the sector ahead of Q3 results. Some see the pullback as a buying opportunity, while others expect more downside.

Aduro Clean Technologies, Inc. engages in the manufacture of oils and specialty chemicals using waste plastics. It focuses on hydrochemolytic technology to transform post-consumer polymer waste into a resource for the circular economy. It also develops a novel chemical conversion process to transform waste plastics and low grade renewable oils into renewable fuels and specialty chemicals. The company was founded on January 10, 2018 by Ofer Vicus and William Marcus Trygstad and is headquartered in London, Canada.

Aduro Clean Technologies Inc

Aduros reported pilot results showing high condensable-hydrocarbon yields across polypropylene and mixed polyolefin feeds are driving discussion, alongside progress toward its planned first-of-a-kind facility. Bulls see the results and engineering work as validation of its plastics-recycling technology, while skeptics argue that yields do not establish commercial economics or scalability.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

Discussion centers on REalloys potential role in a North American rare-earth and magnet supply chain, with traders pointing to U.S. defense sourcing restrictions taking effect in 2027 and the companys Army-linked Tooele project and Tanbreez offtake as longer-term catalysts. Bulls see strategic demand upside, while bears focus on the lack of recent operational updates, execution and dilution risks, and sharp volatility.

Backblaze, Inc. operates as a cloud provider for businesses and consumers to store, use, and protect their data. The firm provides a foundation for businesses, developers, IT professionals, and individuals to store, backup, and archive data, host content, manage media, and build their applications. It also offers B2 Cloud Storage and Computer Backup services. The company was founded by Timothy Nufire, Gleb Budman, Charles Jones, Kwok Hang Ng, Brian Wilson, Nilay Patel and Damon Uyeda in 2007 and is headquartered in San Francisco, CA.

Backblaze Inc - Ordinary Shares - Class A

BLZE is under pressure after a steep pullback, with traders pointing to broader tech weakness and CoreWeaves decline while positioning around the upcoming earnings report. The community is split between dip-buyers betting on strong results or new contracts and cautious traders concerned that earnings could bring further losses.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is falling amid a broad semiconductor selloff that traders attribute largely to Intels weak forward guidance, with some also pointing to bearish put-option activity. The community is split between buying the pullback and expecting further downside, while noting the drop appears tied more to sector pressure than a clear Qualcomm-specific catalyst.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

MAGS is drawing attention amid a pullback and debate over whether mega-cap tech can justify its heavy AI spending, with traders citing cash-flow pressure and bubble risk. Others view the weakness as a buying opportunity and expect money to rotate back from semiconductors into the Magnificent Seven.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002, and is headquartered in Cambridge, MA.

Alnylam Pharmaceuticals Inc

Ionis and AstraZenecas Wainua Phase 3 ATTR-CM trial missed its primary endpoint, drawing attention to potential competitive read-through for Alnylams TTR franchise and upcoming cardiomyopathy pipeline. Traders are divided: some view the failure as removing a rival and strengthening Amvuttras position, while others see it as raising broader questions about TTR silencers and increasing risk around Alnylams development plans.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Health Care Stocks Moving In Wednesday's After-Market Session

Gainers

Biodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 13.3% to $0.55 during Wednesday's after-market session.
Impact BioMedical (AMEX:IBO) stock rose 10.77% to $3.77. The company's market cap stands atread more...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gainers

Biodexa Pharmaceuticals (NASDAQ:BDRX) shares moved upwards by 39.3% to $1.56 during Tuesday's pre-market session. The company's market cap stands at $1.1 million. As per the press release, H1 earningsread more...

Corning, Cellectis, Biodexa Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures fell, with Nasdaq 100 futures down 500 points. Corning dropped 8% after a $2B offering; several other stocks also slid premarket.read more...

12 Health Care Stocks Moving In Friday's Intraday Session

Gainers

Biodexa Pharmaceuticals (NASDAQ:BDRX) shares increased by 110.6% to $1.39 during Friday's regular session.
Tenon Medical (NASDAQ:TNON) shares rose 69.71% to $8.99. The company's market cap stands atread more...

12 Health Care Stocks Moving In Friday's Pre-Market Session

Gainers

Tenon Medical (NASDAQ:TNON) shares moved upwards by 49.2% to $7.91 during Friday's pre-market session. The company's market cap stands at $3.5 million.
Biodexa Pharmaceuticals (NASDAQ:BDRX) stock roseread more...

Insider Signals and Potential Moonshots that Could Reset Valuations

Biotech and pharma markets are leading the way in a sharply selective environment at midday, where clinical data, insider conviction, and platform scalability are driving outsized moves while weaker narratives get left behind. $NTHI, $POET, $SDOT, $BDRX, $CLRB, $DOCN, $FSLY, $EWTX, $BLDP

Why Is Biodexa Pharmaceuticals (BDRX) Stock Skyrocketing Today?

Biodexa Pharmaceuticals shares are trading sharply higher Thursday afternoon after the company said it partnered with Syngene International.read more...

Biodexa Pharmaceuticals Stock Surges 69% Over Partnership With Syngene International

(RTTNews) - Shares of Biodexa Pharmaceuticals Plc (BDRX) are climbing about 69 percent on Thursday morning trading after it announced a partnership with Syngene International Ltd for the manufacture...

Energy Crunch Sparks Sector Rally and Hidden Players Stepping into the Spotlight

A powerful convergence of global energy disruption and emerging technology catalysts is reshaping pockets of the market, with select small-cap names ready to make moves. $SKYQ, $XERI, $KBLB, $TGNT, $BDRX, $COCP

Biodexa Promotes Fiona Sharp To CFO As Stephen Stamp Cedes Role To Become Only CEO

(RTTNews) - Biodexa Pharmaceuticals Plc (BDRX), a clinical stage biopharmaceutical company, Monday announced that it has promoted Fiona Sharp to Chief Financial Officer and Company Secretary...

Biodexa Pharmaceuticals Plc is a drug delivery technology company. The firm is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. Its proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Biodexa Pharmaceuticals Plc - ADR

Biodexa Stock Surges On FDA's Fast-Track Tag For Treatment Of Cancer-Causing Condition: Retail Confidence Peaks

Equity

Neutral Sentiment

Shares of Biodexa Pharmaceuticals skyrocketed nearly 50% on Monday, hitting their highest level since early December.&nbsp;The Cardiff, UK-based company's stock surge followed the U.S. FDA granting its treatment eRapa a Fast Track designation.&nbsp;The drug, a proprietary encapsulated form of rapamycin, is being developed for familial adenomatous polyposis (FAP), a condition that, if left untreated, universally leads to colorectal cancer.&nbsp;FAP currently has no effective medical treatment, with the only option being surgical resection of the colon or rectum.The Fast Track designation aims to expedite the development and review of drugs targeting serious conditions with significant unmet medical needs.&nbsp;Biodexa's Phase 2 study of eRapa showed promising results, with a median 17% reduction in total polyp burden and a 75% non-progression rate at 12 months.&nbsp;In cohort 2, patients showed an even better response, with a 29% median reduction in polyp burden and an 89% non-progression rate.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/BDRX_sentiment_and_message_volume_Feb_10_2beb98885a.png" alt="BDRX sentiment and message volume Feb 10.png" width="1318" height="324"><figcaption>BDRX sentiment and message volume Feb 10 as of 1:45 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment turned 'extremely bullish,' with the stock soaring to the top 10 trending symbols. The volume of messages spiked to its highest level in a year, reflecting increased excitement among investors.&nbsp;Users were optimistic about the stock's potential, with one commenting that it could hit $10 and another suggesting that it was a "last chance to buy in before it goes above $8."&nbsp;<stembedurl>https://stocktwits.com/BULLNATION1/message/603560053</stembedurl><stembedurl>https://stocktwits.com/Mr_Xray/message/603579405</stembedurl>Biodexa's stock has gained around 57% so far this year, though it is still down more than 80% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart | Image source: Maria Korneeva on Getty Images

The drug, a proprietary encapsulated form of rapamycin, is being developed for familial adenomatous polyposis (FAP), a condition that, if left untreated, universally leads to colorectal cancer. 

Biodexa Pharmaceuticals Plc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$3.43
Prev Close	$3.90
Open	$3.83
Dividend Yield	0.00%
50-Day Moving Average	$5.58
Beta	1.22
Avg. Volume	1.26M
PE Ratio	-0.06

52-Week High	$357.60
52-Week Low	$2.70
Market Capitalization	$441,200.00
EPS (Annual)	-$632.59
Price to Book	2,700.79
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

BDRX Fundamentals